Javascript must be enabled to continue!
Building the European Nanomedicine Research and Innovation Area: 10 years funding innovative research projects
View through CrossRef
EuroNanoMed (ENM) is an ERA-NET for nanomedicine. ERA.NET is an EU funded network which had been established to support and increase the coordination of European research programmes and related funding. It is a platform for funding agencies and ministries to develop joint activities and programmes with the aim of coordinating high-quality research in diverse research fields, in this case nanomedicine, across national borders. It has been 10 years since the establishment of EuroNanoMed presently in its third phase. For those 10 years, Research and Innovation funding organizations in Europe and beyond have been joining forces to fund excellent innovative research projects in the main 3 topics defined by the European Technology Platform on Nanomedicine: targeted drug delivery, diagnostics and regenerative medicine. Ten joint transnational calls have been launched (the 10th call is ongoing). So far, 90 transnational projects have been funded, including 460 research groups from over 20 countries. In the Joint Transnational Call 2017—co-funded by national and regional funding organizations and the European Commission—16 projects were funded with a total investment of 14 million euros, including 3.3 million euros from the European Commission. In addition to EuroNanoMed's main activity of funding transnational innovative research projects, it collaborates with sister initiatives in nanomedicine and translational research. ENM has organised review seminars as well as safety, ethics and regulatory affairs training workshops. The purpose of this article is to summarise the activities of EuroNanoMed over the last 10 years.
Title: Building the European Nanomedicine Research and Innovation Area: 10 years funding innovative research projects
Description:
EuroNanoMed (ENM) is an ERA-NET for nanomedicine.
ERA.
NET is an EU funded network which had been established to support and increase the coordination of European research programmes and related funding.
It is a platform for funding agencies and ministries to develop joint activities and programmes with the aim of coordinating high-quality research in diverse research fields, in this case nanomedicine, across national borders.
It has been 10 years since the establishment of EuroNanoMed presently in its third phase.
For those 10 years, Research and Innovation funding organizations in Europe and beyond have been joining forces to fund excellent innovative research projects in the main 3 topics defined by the European Technology Platform on Nanomedicine: targeted drug delivery, diagnostics and regenerative medicine.
Ten joint transnational calls have been launched (the 10th call is ongoing).
So far, 90 transnational projects have been funded, including 460 research groups from over 20 countries.
In the Joint Transnational Call 2017—co-funded by national and regional funding organizations and the European Commission—16 projects were funded with a total investment of 14 million euros, including 3.
3 million euros from the European Commission.
In addition to EuroNanoMed's main activity of funding transnational innovative research projects, it collaborates with sister initiatives in nanomedicine and translational research.
ENM has organised review seminars as well as safety, ethics and regulatory affairs training workshops.
The purpose of this article is to summarise the activities of EuroNanoMed over the last 10 years.
Related Results
Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT
Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT
Abstract
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndromes (MDS). Several studie...
Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma
Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma
Background: Lytic bone lesions are one of the most common clinical characteristics of patients with multiple myeloma (MM) and identification of bone lesions help distinguish betwee...
Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia
Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia
BACKGROUND
Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma in which bone marrow is infiltrated by immunoglobulin M (IgM)-producing clonal lymphopl...
Improvement of Innovative Projects Management and Revival of Innovation Activities of Ukrainian Enterp
Improvement of Innovative Projects Management and Revival of Innovation Activities of Ukrainian Enterp
Introduction. The wider application of the benefits of project management in the organization of innovation is seen as an effective tool for revitalizing the innovation activities ...
Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation
Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation
Abstract
BACKGROUND: Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) entails sudden life changes including acute symptom burden, changes in phy...
Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Abstract
Background:
GLUT4 inhibition is an attractive therapeutic option in multiple myeloma (MM) given the dependence of MM cells on glucose transpo...
Towards a Democratisation of Innovation
Towards a Democratisation of Innovation
Singapore is an innovation-intensive nation. In 2020 Prime Minister Lee Hsien Loong pledged to inject ‘up to S$150million’ in the country’s startup ecosystem (Channel News Asia). T...
Combining the Number of Infectious Episodes and Interval of Chemotherapy to Transplantation May Predict a Transplant Outcome in Patients with Acute Myeloid Leukemia: A Retrospective Analysis of JALSG AML201 Study
Combining the Number of Infectious Episodes and Interval of Chemotherapy to Transplantation May Predict a Transplant Outcome in Patients with Acute Myeloid Leukemia: A Retrospective Analysis of JALSG AML201 Study
Abstract
Background
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for acute myeloid leukemia (AML),...

